Form 4 Filing for Aura Biosciences, Inc.

Jeremy Bender, a director at Aura Biosciences, Inc., reported a transaction on July 7, 2026. Bender acquired 30,000 shares of Common Stock under the Issuer's 2021 Stock Option and Incentive Plan, with these shares vesting in installments starting July 15, 2027. Additionally, Bender was granted an option to acquire 60,000 shares of Common Stock, with an exercise price of $7.03 per share. This option also vests in three equal annual installments beginning July 7, 2027. Both transactions are reported as direct ownership. The filing was signed by Conor Kilroy as Attorney-in-Fact on July 8, 2026.